We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Shares of Tilly’s, Inc. (TLYS - Free Report) fell more than 22% during the trading session on Jan 13, after the retailer revealed sluggish holiday sales numbers and slashed view. Despite a robust Black Friday weekend and Cyber Monday, a sudden deceleration in sales and traffic in the second and third weeks of December weighed on the results of the holiday period.
Notably, comparable store sales declined 2% for the nine weeks, ended Jan 5, 2019, against growth of 5.8% in the prior-year period. The company witnessed dismal results in most of the geographical markets, except for New England, the Upper Midwest and Arizona. We note that the Southeast, Florida and Nevada regions were most affected in terms of comparable-store sales.
Further, comparable store sales in physical stores, which accounted for 80.5% of total sales in the nine weeks, slumped 2.7%. Meanwhile, e-commerce sales, which contributed 19.5% to total sales in the said period, inched up 1%. Moreover, comparable store sales for girls’ and women’s merchandises were positive but were more than offset by softness in other merchandising categories such as footwear and accessories.
Total sales for the nine weeks were $143.9 million, up 1.1% from $142.4 million reported in the prior-year period.
Owing to dismal results, management trimmed its fourth-quarter fiscal 2019 outlook. The company now anticipates a 2-3% decline in comparable store sales, whereas it earlier mentioned 2-5% growth. Adjusted earnings are expected to be 18-20 cents, down from 29-32 cents stated previously.
Nonetheless, the Zacks Rank #1 (Strong Buy) stock is leaving no stone unturned to get back on track. In this regard, store expansion plans, especially in the Northeast, comprising Texas and Chicago regions, along with improved loyalty program and investment in customer-facing technologies bode well. Such well chalked out efforts may provide some cushion to the stock, which has declined 7% in the past three months against the industry’s growth of 8.1%.
Best Buy (BBY - Free Report) presently has a long-term earnings growth rate of 8.7% and a Zacks Rank #2 (Buy).
Target Corp. (TGT - Free Report) currently has a long-term earnings growth rate of 7.6% and a Zacks Rank #2.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Tilly's (TLYS) Stock Dips on Dismal Holiday Sales & View Cut
Shares of Tilly’s, Inc. (TLYS - Free Report) fell more than 22% during the trading session on Jan 13, after the retailer revealed sluggish holiday sales numbers and slashed view. Despite a robust Black Friday weekend and Cyber Monday, a sudden deceleration in sales and traffic in the second and third weeks of December weighed on the results of the holiday period.
Notably, comparable store sales declined 2% for the nine weeks, ended Jan 5, 2019, against growth of 5.8% in the prior-year period. The company witnessed dismal results in most of the geographical markets, except for New England, the Upper Midwest and Arizona. We note that the Southeast, Florida and Nevada regions were most affected in terms of comparable-store sales.
Further, comparable store sales in physical stores, which accounted for 80.5% of total sales in the nine weeks, slumped 2.7%. Meanwhile, e-commerce sales, which contributed 19.5% to total sales in the said period, inched up 1%. Moreover, comparable store sales for girls’ and women’s merchandises were positive but were more than offset by softness in other merchandising categories such as footwear and accessories.
Total sales for the nine weeks were $143.9 million, up 1.1% from $142.4 million reported in the prior-year period.
Owing to dismal results, management trimmed its fourth-quarter fiscal 2019 outlook. The company now anticipates a 2-3% decline in comparable store sales, whereas it earlier mentioned 2-5% growth. Adjusted earnings are expected to be 18-20 cents, down from 29-32 cents stated previously.
Nonetheless, the Zacks Rank #1 (Strong Buy) stock is leaving no stone unturned to get back on track. In this regard, store expansion plans, especially in the Northeast, comprising Texas and Chicago regions, along with improved loyalty program and investment in customer-facing technologies bode well. Such well chalked out efforts may provide some cushion to the stock, which has declined 7% in the past three months against the industry’s growth of 8.1%.
Check Out These Other Solid Picks
Zumiez Inc (ZUMZ - Free Report) has a long-term earnings growth rate of 12%. It currently sports a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.
Best Buy (BBY - Free Report) presently has a long-term earnings growth rate of 8.7% and a Zacks Rank #2 (Buy).
Target Corp. (TGT - Free Report) currently has a long-term earnings growth rate of 7.6% and a Zacks Rank #2.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>